Clinical trials: Pharmacogenomic Testing
Pulmonary Arterial Hypertension, Pulmonary Hypertension
Pharmacogenomics in Pulmonary Arterial Hypertension
Our goal is to determine clinically in Pulmonary Arterial Hypertension patients if associations exist between the efficacy and toxicity of sitaxsentan, bosentan, and ambrisentan and several gene polymorphisms in several key…
- Conditions
- Pulmonary Arterial Hypertension, Pulmonary Hypertension, PAH WHO Group I
- Trial name
- NCT00593905
- Testing
- Sitaxsentan, Bosentan, Ambrisentan
- Where
- United States
- Sponsor
- West Penn Allegheny Health System
Pediatric Cancer
Pharmacogenomic Testing in Pediatric Hematology/Oncology Patients
Pharmacogenomic (PGx) testing involves analyzing variants of genes associated with drug metabolism, transport and medication targets.
- Trial name
- NCT06744712
- Testing
- Pharmacogenomic Testing
- Where
- United States
- Volunteers
- 130 people
- Sponsor
- Wake Forest University Health Sciences
Gastroesophageal Reflux
Implementation of PPI Medication PGX Testing
Using genetic information about the individual to pick the right drug for the right disease at the right dose defines personalized medicine.
- Trial name
- PGX (NCT02794844)
- Testing
- Genotype Guided PPI Dosing
- Where
- United States
- Volunteers
- 28 people
- Sponsor
- Nemours Children's Clinic
Pharmacogenomic Testing
VICE-MPRINT: Maternal and Pediatric Pharmacogenetics Survey
The field of pharmacogenetics has progressed from the discovery of genetic variants that cause variable function of drug metabolism enzymes to a cornerstone of clinical precision medicine.
- Trial name
- MPRINT (NCT05037305)
- Testing
- Educational video
- Where
- 2 sites in United States
- Volunteers
- 798 people, healthy volunteers welcome
- Sponsor
- Vanderbilt University Medical Center
Adverse Drug Reaction (ADR)
Integrating Pediatric Pharmacogenomic Testing Into the Canadian Health Care System
This project addresses the problem of adverse drug reactions in the three most frequently prescribed therapeutic classes of drugs in children: antibiotics, analgesics, and mental health medications.
- Trial name
- NCT04249375
- Where
- 2 sites in Canada
- Volunteers
- 150 people
- Sponsor
- University of British Columbia
Target Drug-related Adverse Events
Standard of Care Versus Urine Testing With Selective PHarmacogenomics for Effective Drug and Dosing REgimens
The purpose of this study is to determine whether the addition of selective pharmacogenomic (PGx) testing as determined by Urine Drug Testing (UDT) adds a clinical benefit as evidenced by a reduction in Target Drug-related…
- Trial name
- SPHERE (NCT02625155)
- Testing
- Urine diagnostic testing as SOC, drug regimen changes per SOC, Urine diagnostic testing with selective PGx testing, drug regimen changes based on PGx test results
- Where
- United States
- Volunteers
- 14,000 people, healthy volunteers welcome
- Sponsor
- InSource Diagnostics
Machine Learning, Prediction Models
Timely Ordering of Pharmacogenetic Testing
The goal of this trial is to learn if a machine learning (ML) model can help optimize drug therapy in the pediatric population. The main question[s] it aims to answer are whether a machine learning model predicting receipt of a…
- Conditions
- Machine Learning, Prediction Models, Pediatrics, Precision Medicine
- Trial name
- NCT06902688
- Testing
- ML-based intervention
- Where
- Canada
- Volunteers
- 275 people
- Sponsor
- The Hospital for Sick Children
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Pharmacogenomics Testing in the Optimal Use of Supportive Care Medications in Stage III-IV Cancer
This early phase I trial studies how well a genetic test called pharmacogenomics works in directing the optimal use of supportive care medications in patients with stage III-IV cancer.
- Conditions
- Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8
- Trial name
- NCT04067960
- Testing
- Biospecimen Collection, Genetic Testing, Quality-of-Life Assessment
- Where
- United States
- Volunteers
- 197 people, healthy volunteers welcome
- Sponsor
- Mayo Clinic
Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis
HLA-B*58:01-Guided Therapy for Gout: Effectiveness, Safety, and Cost-Effectiveness
Severe cutaneous adverse reactions (SCARs), such as Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) and drug reaction with eosinophilia and systemic symptoms (DRESS), are rare but life-threatening complications that…
- Conditions
- Gout Initiating Urate-loweringUrate-lowering Therapy, Gout Arthritis, Gout and Hyperuricemia
- Trial name
- HLA-SCREEN (NCT07369622)
- Testing
- HLA-B*58:01 Genotyping, Allopurinol Tablet, Febuxostat
- Volunteers
- 228 people, healthy volunteers welcome
- Sponsor
- Haiphong University of Medicine and Pharmacy
Congenital Bleeding Disorder, Haemophilia A With Inhibitors
Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial
This study is conducted globally. This study describes pharmacogenetic testing of saliva samples from patients who participated in the NN1731-3562 trial (adept™2) (NCT01392547).
- Conditions
- Congenital Bleeding Disorder, Haemophilia A With Inhibitors, Haemophilia B With Inhibitors
- Trial name
- NCT02541942
- Testing
- No treatment given
- Where
- 15 sites in United States, Greece and 5 more
- Volunteers
- 19 people
- Sponsor
- Novo Nordisk A/S
Attention Deficit Disorders With Hyperactivity
Pharmacogenomics for Improving Pediatric ADHD Treatment
This research study is a randomized controlled trial (RCT) to test whether pharmacogenomics (PGx) testing for ADHD medications will help guide clinicians to choose medications and dosages for pediatric ADHD treatment that provide…
- Trial name
- NCT03730870
- Testing
- Pharmacogenomics report
- Where
- 3 sites in United States
- Volunteers
- 21 people
- Sponsor
- Clinical and Translational Genome Research Institute, Inc.
Gastroesophageal Reflux
Pharmacogenetic Testing in Children With Persistent Gastroesophageal Reflux Disease
This study will use a 22 gene pharmacogenomics panel on 30 children with persistent Gastroesophageal Reflux Disease (GERD) who have not responded to therapy.
- Trial name
- NCT03005080
- Where
- United States
- Volunteers
- 51 people
- Sponsor
- Mayo Clinic
Schizophrenia, Schizoaffective Disorder
Prospective Pharmacogenetic Testing and Clinical Outcomes in Patients With Early-Phase Psychosis
This study evaluates whether prospective pharmacogenetic testing is cost-effective in affecting clinical treatment outcomes in patients with early-phase psychosis.
- Conditions
- Schizophrenia, Schizoaffective Disorder, Schizophreniform Disorder, Psychotic Disorders
- Trial name
- NCT02566057
- Testing
- PGx testing guided treatment (PGT)
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Northwell Health
Healthy
Efficacy of Personal Pharmacogenomic Testing as an Educational Tool in the Pharmacy Curriculum
The purpose of this study is to evaluate the use of personal genomic educational testing (PGET) on student knowledge and clinical skills surrounding pharmacogenomic testing to ensure it is of educational benefit to our student…
- Trial name
- NCT04889014
- Testing
- Personal genomic educational testing (PGET), No personal genomic educational testing (NPGET)
- Volunteers
- 233 people, healthy volunteers welcome
- Sponsor
- University of Arizona
All Malignancies, Children Being Treated for Catastrophic Illness
Pharmacogenetic Determinants Of Treatment Response In Children
To investigate whether genetic polymorphisms in genes encoding proteins involved in the metabolism or effects of drugs or environmental agents influence the disposition or effects of these xenobiotic substrates.
- Trial name
- NCT00730678
- Where
- United States
- Volunteers
- 8,800 people, healthy volunteers welcome
- Sponsor
- St. Jude Children's Research Hospital
Obsessive Compulsive Disorder, Major Depressive Disorder
Integrating Pharmacogenomic Testing Into a Child Psychiatry Clinic
The purpose of this study is to examine the feasibility, acceptability, and utility of pharmacogenomic (PGX) testing (specifically for the cytochrome P450 2D6 and 2C19 genes) prior to initiating treatment with an antidepressant…
- Conditions
- Obsessive Compulsive Disorder, Major Depressive Disorder, Anxiety
- Trial name
- PGX (NCT02855580)
- Where
- United States
- Volunteers
- 71 people, healthy volunteers welcome
- Sponsor
- University of Florida
Adverse Drug Reaction, Therapy Failure
Pharmacogenetic Testing of Patients With Unwanted Adverse Drug Reactions or Therapy Failure
Genetic makeup of a patient influences the efficacy and safety profile of a drug. This study is to summarize individual cases, where Pharmacogenetics (PGx) has been applied during pharmaceutical care.
- Trial name
- NCT04154553
- Testing
- Buccal swab, EDTA Blood sample (4.9mL), Serum sample (7.5mL)
- Where
- Switzerland
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- University Hospital, Basel, Switzerland